The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is low. Over the past 30 days, multiple analysts have rated the company as a . Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Predictive Oncology Inc's Score
Industry at a Glance
Industry Ranking
227 / 407
Overall Ranking
449 / 4616
Industry
Biotechnology & Medical Research
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
3.000
Target Price
+251.62%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Predictive Oncology Inc Highlights
StrengthsRisks
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.62M.
Fairly Valued
The company’s latest PE is -0.41, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 12.13K shares, decreasing 63.68% quarter-over-quarter.
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.